litlas
Log inCreate account

Sherene Loi

Active 2005–2026

309
Papers
75,943
Citations
127
h-index
296
i10-index

Citations

Citations per year for Sherene Loi1964: 3 citations1971: 1 citations1984: 1 citations1988: 1 citations1993: 2 citations1999: 11 citations2001: 2 citations2003: 2 citations2005: 2 citations2006: 20 citations2007: 65 citations2008: 183 citations2009: 183 citations2010: 243 citations2011: 212 citations2012: 234 citations2013: 289 citations2014: 338 citations2015: 470 citations2016: 646 citations2017: 814 citations2018: 826 citations2019: 2,929 citations2020: 4,144 citations2021: 5,040 citations2022: 4,283 citations2023: 3,469 citations2024: 4,898 citations2025: 2,804 citations2026: 102 citations1965–1970: no citations, so these years are not shown1972–1983: no citations, so these years are not shown1985–1987: no citations, so these years are not shown1989–1992: no citations, so these years are not shown1994–1998: no citations, so these years are not shown2000: no citations, so this year is not shown2002: no citations, so this year is not shown2004: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,234 citing papers, 22.4% of this breakdownChina: 4,934 citing papers, 15.2% of this breakdownItaly: 1,812 citing papers, 5.6% of this breakdownUnited Kingdom: 1,733 citing papers, 5.4% of this breakdownGermany: 1,474 citing papers, 4.5% of this breakdownFrance: 1,396 citing papers, 4.3% of this breakdownSpain: 1,088 citing papers, 3.4% of this breakdownAustralia: 1,082 citing papers, 3.3% of this breakdownCanada: 993 citing papers, 3.1% of this breakdownJapan: 887 citing papers, 2.7% of this breakdownBelgium: 863 citing papers, 2.7% of this breakdownNetherlands: 735 citing papers, 2.3% of this breakdown
0%22.4%Other 25.1%

Institutions

Fields

  • Medicine54.8%
  • Biochemistry, Genetics and Molecular Biology30.1%
  • Immunology and Microbiology8.7%
  • Computer Science2.1%
  • Engineering1.9%
  • Materials Science0.5%
  • Other1.9%

Topics

  • Cancer Immunotherapy and Biomarkers10.1%
  • Immunotherapy and Immune Responses4.8%
  • Advanced Breast Cancer Therapies4.3%
  • Breast Cancer Treatment Studies4.2%
  • HER2/EGFR in Cancer Research3.9%
  • Cancer Genomics and Diagnostics3.4%
  • Other69.3%

Coauthors

All papers

Open in search
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Authors: Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Roberto Hegg, Seock‐Ah Im, Gail S. Wright, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Roel Funke, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - New England Journal of Medicine 2018 cited by 4,369

  2. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

    Authors: Javier Cortés, Hope S. Rugo, David W. Cescon, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, José Manuel Pérez-García, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gokmen, Sherene Loi, Zifang Guo, Xuan Zhou, Vassiliki Karantza, Wilbur Pan, Peter Schmid - New England Journal of Medicine 2022 cited by 1,096

  3. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

    Authors: Alessandra Gennari, Fabrice André, Carlos H. Barrios, Javier Cortés, Evandro de Azambuja, A. DeMichele, Rebecca Dent, Deborah Fenlon, Joseph Gligorov, Sara A. Hurvitz, Seock‐Ah Im, David Krug, Wolfgang G. Kunz, Sherene Loi, Frédérique Penault‐Llorca, Jens Ricke, Mark E. Robson, Hope S. Rugo, Cristina Saura, Peter Schmid, Christian F. Singer, Tanja Španić, Sara M. Tolaney, Nicholas C. Turner, Giuseppe Curigliano, Sibylle Loibl, Shani Paluch–Shimon, Nadia Harbeck - Annals of Oncology 2021 cited by 1,367

  4. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

    Authors: Javier Cortés, David W. Cescon, Hope S. Rugo, Zbigniew Nowecki, Seock‐Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H. Barrios, Esther Holgado, Hiroji Iwata, Norikazu Masuda, Marco Torregroza Otero, Erhan Gökmen, Sherene Loi, Zifang Guo, Jing Zhao, Gursel Aktan, Vassiliki Karantza, Peter Schmid, F. Vidal Luis, Gomez Abuin Gonzalo, Diego Kaen, Kowalwszyn Ruben, Molina Matias, Varela Mirta, Sally Baron-Hay, Begbie Stephen, Clingan Philip, Loi Sherene, Sabanathan Dhanusha, Andrea Gombos, Donatienne Taylor, Carlos Barrios, Leandro Brust, Costa Fabiano, de Freitas Junior Ruffo, Roberto Hegg, Lacerda Domicio Carvalho, Lissa Fernando Cezar Toniazzi, Rocha Roberto Odebrecht, Scalabrini Neto Antonio Orlando, Silva Felipe, Cescon David, Danielle Charpentier, Ferrario Cristiano, Xinni Song, Yu Joanne, Alejandro Acevedo, Gallardo Carlos, Salas Claudio, Sanchez Cesar, Eduardo Yañez, Gomez Diaz Alvaro, Sanchez Jesus, Holeckova Petra, Kral Zdenek, Bohuslav Melichar, Katarína Petráková, Prausova Jana, Vesna Glavicic, Jakobsen Erik, Jensen Jeanette, Søren Linnet, Tamás Lörincz, Bonnefoi Herve, Isabelle Desmoulins, Goncalves Anthony, Hardy-Bessard Anne-Claire, Luís Teixeira, Blohmer Jens-Uwe, Fasching Peter, Dirk Forstmeyer, Nadia Harbeck, Huober Jens, Kaczerowsky Flores de Sousa Anna, Kurbacher Christian, Sibylle Loibl, Lueftner Diana, Park-Simon Tjoung-Won, Schumann Raquel Von, Pauline Wimberger, Chow Louis, Kwong Ava, Ngan Kai Cheong Roger, Peter Arkosy, Tibor Csőszi, Zsuzsanna Kahán, Landherr László, Mahr Karoly, Gábor Rubovszky, Crown John, Kelly Catherine, O'Reilly Seamus, Saverio Cinieri, DAlessio Antonietta, Ricevuto Enrico, Tomoyuki Aruga, Takaaki Fujii, Inoue Kenichi and 127 more - The Lancet 2020 cited by 1,800

  5. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    Authors: Roberto Salgado, Carsten Denkert, Sandra Demaria, Nicolas Sirtaine, Frederick Klauschen, Giancarlo Pruneri, Stephan Wienert, Gert Van den Eynden, Frederick L. Baehner, Frédérique Penault‐Llorca, Edith A. Perez, E. Aubrey Thompson, W. Fraser Symmans, Andrea L. Richardson, Jane Brock, Carmen Criscitiello, Helen D. Bailey, M. Ignatiadis, Giuseppe Floris, Joseph A. Sparano, Zuzana Kos, Torsten O. Nielsen, David L. Rimm, Kimberly H. Allison, Jorge S. Reis‐Filho, Sibylle Loibl, Christos Sotiriou, Giuseppe Viale, Sunil Badve, Sylvia Adams, Karen Willard‐Gallo, Sherene Loi - Annals of Oncology 2014 cited by 3,136

  6. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

    Authors: Sara A. Hurvitz, Roberto Hegg, Wei‐Pang Chung, Seock‐Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altıntaş, Jan‐Willem Henning, Giuseppe Curigliano, José Manuel Pérez-García, Sung‐Bae Kim, Vanessa Petry, Chiun‐Sheng Huang, Wěi Li, Jean‐Sébastien Frenel, Silvia Antolín, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés - The Lancet 2022 cited by 642

  7. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Authors: Lorenzo Galluzzi, Ilio Vitale, Sarah H. Warren, Sandy Adjemian, Patrizia Agostinis, Aitziber Buqué Martinez, Timothy A. Chan, George Coukos, Sandra Demaria, Éric Deutsch, Dobrin Draganov, Richard L. Edelson, Silvia C. Formenti, Jitka Fučíková, Lucia Gabriele, Udo S. Gaipl, Sofia R. Gameiro, Abhishek D. Garg, Encouse B. Golden, Jian Han, Kevin J. Harrington, Akseli Hemminki, James W. Hodge, Dewan Md Sakib Hossain, Tim Illidge, Michael Karin, Howard L. Kaufman, Oliver Kepp, Guido Kroemer, Juan José Lasarte, Sherene Loi, Michael T. Lotze, Gwenola Manic, Taha Merghoub, Alan Melcher, Karen Mossman, Felipe Prósper, Øystein Rekdal, María Rescigno, Chiara Riganti, Antonella Sistigu, Mark J. Smyth, Radek Špíšek, John Stagg, Bryan E. Strauss, Daolin Tang, Kazuki Tatsuno, Stefaan Van Gool, Peter Vandenabeele, Takahiro Yamazaki, Dmitriy Zamarin, Laurence Zitvogel, Alessandra Cesano, Francesco M. Marincola - Journal for ImmunoTherapy of Cancer 2020 cited by 1,061

  8. Intratumoral heterogeneity in cancer progression and response to immunotherapy

    Authors: Ilio Vitale, Efrat Shema, Sherene Loi, Lorenzo Galluzzi - Nature Medicine 2021 cited by 838

  9. Embracing cancer complexity: Hallmarks of systemic disease

    Authors: Charles Swanton, Elsa Bernard, Chris Abbosh, Fabrice André, Johan Auwerx, Allan Balmain, Dafna Bar‐Sagi, René Bernards, Susan Bullman, James DeGregori, Catherine Elliott, Ayelet Erez, Gérard I. Evan, Mark A. Febbraio, Andrés Hidalgo, Mariam Jamal‐Hanjani, Johanna A. Joyce, Matthew Kaiser, Katja Lamia, Jason W. Locasale, Sherene Loi, Ilaria Malanchi, Miriam Mérad, Kathryn Musgrave, Ketan Patel, Sergio A. Quezada, Jennifer A. Wargo, Ashani T. Weeraratna, Eileen White, Frank Winkler, John N. Wood, Karen H. Vousden, Douglas Hanahan - Cell 2024 cited by 507

  10. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

    Authors: Imran G. House, Peter Savas, Junyun Lai, Amanda X. Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis - Clinical Cancer Research 2019 cited by 766

  11. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Vidya Maiya, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - The Lancet Oncology 2019 cited by 1,198

  12. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

    Authors: Peter Savas, Balaji Virassamy, Chengzhong Ye, Agus Salim, Christopher Mintoff, Franco Caramia, Roberto Salgado, David J. Byrne, Zhi L. Teo, Sathana Dushyanthen, Ann Byrne, Lironne Wein, Stephen J. Luen, Catherine Poliness, Sophie Nightingale, Anita Skandarajah, David Gyorki, Chantel M. Thornton, Paul A. Beavis, Stephen B. Fox, Phillip K. Darcy, Terence P. Speed, Laura K. Mackay, Paul J. Neeson, Sherene Loi - Nature Medicine 2018 cited by 991

  13. Neoantigen-directed immune escape in lung cancer evolution

    Authors: Rachel Rosenthal, Elizabeth Larose Cadieux, Roberto Salgado, Maise Al Bakir, David A. Moore, Crispin T. Hiley, Tom Lund, Miljana Tanić, James L. Reading, Kroopa Joshi, Jake Y. Henry, Ehsan Ghorani, Gareth A. Wilson, Nicolai J. Birkbak, Mariam Jamal‐Hanjani, Selvaraju Veeriah, Zoltán Szállási, Sherene Loi, Matthew D. Hellmann, Andrew Feber, Benny Chain, Javier Herrero, Sergio A. Quezada, Jonas Demeulemeester, Peter Van Loo, Stephan Beck, Nicholas McGranahan, Charles Swanton - Nature 2019 cited by 993

  14. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon - The Lancet Oncology 2016 cited by 1,822

  15. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Authors: Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-­Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim and 122 more - The Lancet Oncology 2020 cited by 898

  16. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Authors: Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro, Igor Bondarenko, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Fabrice André, Kathy Puyana Theall, Xin Huang, C. Giorgetti, Cynthia Huang Bartlett, Massimo Cristofanilli - New England Journal of Medicine 2018 cited by 1,293

  17. CD4+ follicular helper T cell infiltration predicts breast cancer survival

    Authors: Chunyan Gu‐Trantien, Sherene Loi, Soizic Garaud, Carole Equeter, Myriam Libin, Alexandre de Wind, Marie Ravoet, Hélène Le Buanec, Catherine Sibille, Germain Manfouo-Foutsop, Isabelle Veys, Benjamin Haibe‐Kains, Sandeep K. Singhal, Stefan Michiels, Françoise Rothé, Roberto Salgado, Hugues Duvillier, Michail Ignatiadis, Christine Desmedt, Dominique Bron, Denis Larsimont, Martine Piccart, Christos Sotiriou, Karen Willard‐Gallo - Journal of Clinical Investigation 2013 cited by 1,050

  18. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

    Authors: Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroji Iwata, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Eric P. Winer, Shilpen Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, Shilpen Patel, S.Y. Chui, P. Schmid - Annals of Oncology 2021 cited by 468

  19. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: Nicholas C. Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang, C. Giorgetti, Sophia Randolph, María Koehler, Massimo Cristofanilli - New England Journal of Medicine 2015 cited by 1,586

  20. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

    Authors: Sylvia Adams, P. Schmid, H. S. Rugo, EP Winer, D. Loirat, Ahmad Awada, D.W. Cescon, Hiromitsu Iwata, M. Campone, Rita Nanda, Rita L. Hui, Giuseppe Curigliano, D. Toppmeyer, Joyce O’Shaughnessy, Sherene Loi, Shani Paluch–Shimon, Antoinette R. Tan, Deborah Card, Jing Zhao, V. Karantza, Javier Cortés - Annals of Oncology 2018 cited by 795

  21. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

    Authors: Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A. Francis, Magali Lacroix‐Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert J. Gray, Elisabetta Munzone, Jérôme Lemonnier, Christos Sotiriou, Martine Piccart, Pirkko‐Liisa Kellokumpu‐Lehtinen, Andrea Vingiani, Kathryn P. Gray, Fabrice André, Carsten Denkert, Roberto Salgado, Stefan Michiels - Journal of Clinical Oncology 2019 cited by 891

  22. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

    Authors: Ben O’Leary, Rosalind Cutts, Yuan Liu, Sarah Hrebien, Xin Huang, Kerry Fenwick, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac García-Murillas, Massimo Cristofanilli, Cynthia Huang Bartlett, Nicholas C. Turner - Cancer Discovery 2018 cited by 667

  23. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

    Authors: Samra Turajlic, Kevin Litchfield, Hang Xu, Rachel Rosenthal, Nicholas McGranahan, James L. Reading, Yien Ning Sophia Wong, Andrew Rowan, Nnennaya Kanu, Maise Al Bakir, Tim Chambers, Roberto Salgado, Peter Savas, Sherene Loi, Nicolai J. Birkbak, Laurent Sansregret, Martin Gore, James Larkin, Sergio A. Quezada, Charles Swanton - The Lancet Oncology 2017 cited by 933

  24. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    Authors: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 cited by 357